AI주식인사이트AI Stock Insight
B

하이텍팜

106190KOSDAQ기초 의약물질 제조업

63.5 / 100

Reference Date: 2026-04-13

Financial Score28.0 / 40
News Sentiment12.5 / 25
Momentum13.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Surged 23.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Hitek Pharm is a specialized pharmaceutical company established in 1998, focusing on carbapenem-class antibiotic APIs. Its flagship products, imipenem and ertapenem, leverage strong antibacterial properties and high price competitiveness, with exports accounting for 99.99% of sales, primarily to Europe and Asia. In 2023, the company achieved sales of 77.5 billion KRW and operating profit of 15.56 billion KRW, demonstrating sustained growth.

Number of Employees

130people

Average Salary

59.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
18.04Industry Average 33.456.5Point

Lower than industry avg (good)

PBR
1.58Industry Average 2.034.0Point

In line with industry avg

ROE
9.17Industry Average -4.293.5Point

Well below industry avg

Debt Ratio
0.39Industry Average 6.618.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
0.5 / 3

Avg ▼4.2% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲18.4% (2-year basis)

ROE Trend
3.0 / 4

Avg ROE 9.7% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position6.0Point

52w upper range (60%)

Current 19,470Won52-week high 25,00052-week low 10,870
1-month return6.0Point

1m +22.99% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

9 totalPositive 0Neutral 9Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-03-31
  • Neutral주식매수선택권행사2026-03-31
  • Neutral주식등의대량보유상황보고서(일반)2026-03-30
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-27
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-27